A Study to Evaluate Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With Breast Cancer
Conditions: Breast Cancer; HER2+ Breast Cancer Interventions: Biological: VRP-HER2; Biological: Pembrolizumab Sponsors: Herbert Lyerly; Merck Sharp & Dohme Corp. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials